280 related articles for article (PubMed ID: 30982303)
41. The polymorphous spectrum of dermatomyositis: classic features, newly described skin lesions, and rare variants.
Didona D; Juratli HA; Scarsella L; Eming R; Hertl M
Eur J Dermatol; 2020 Jun; 30(3):229-242. PubMed ID: 32666925
[TBL] [Abstract][Full Text] [Related]
42. [Dermatomyositis-specific antibodies].
Bodoki L; Nagy-Vincze M; Griger Z; Dankó K
Z Rheumatol; 2015 May; 74(4):363-9. PubMed ID: 25644067
[TBL] [Abstract][Full Text] [Related]
43. Dermatomyositis revealing breast cancer: report of a case.
Lamquami S; Errarhay S; Mamouni N; Bouchikhi C; Banani A
Pan Afr Med J; 2015; 21():89. PubMed ID: 26491532
[TBL] [Abstract][Full Text] [Related]
44. Amyopathic and anti-TIF1 gamma-positive dermatomyositis: analysis of a monocentric cohort and proposal to update diagnostic criteria.
Didona D; Juratli HA; Scarsella L; Keber U; Eming R; Hertl M
Eur J Dermatol; 2020 Jun; 30(3):279-288. PubMed ID: 32666928
[TBL] [Abstract][Full Text] [Related]
45. A Case in Which Breast Cancer Developed at the Same Time As Dermatomyositis, and the Onset of New Cancer Was Able to Be Predicted by the Exacerbating Skin Symptoms and Parallel Increase in the Anti-TIF1-γ Antibody Levels.
Akagi H; Wada T
Intern Med; 2023; 62(20):3057-3062. PubMed ID: 37839875
[TBL] [Abstract][Full Text] [Related]
46. A novel autoantibody to a 155-kd protein is associated with dermatomyositis.
Targoff IN; Mamyrova G; Trieu EP; Perurena O; Koneru B; O'Hanlon TP; Miller FW; Rider LG; ;
Arthritis Rheum; 2006 Nov; 54(11):3682-9. PubMed ID: 17075819
[TBL] [Abstract][Full Text] [Related]
47. Anti-TIF1-γ autoantibodies-positive dermatomyositis: where is the malignancy?
Zachou A; Zouvelou V; Papadimas GK; Rentzos M; Papadopoulos C
Rheumatology (Oxford); 2018 Apr; 57(4):756. PubMed ID: 28968891
[No Abstract] [Full Text] [Related]
48. Anti-NXP2-Positive Paraneoplastic Dermatomyositis With Histopathologic Changes Confined to the Acrosyringia.
Ramírez-Bellver JL; Macías E; Bernárdez C; López-Robles J; Vegas-Sánchez MD; Díaz-Recuero JL; Quiceno H; Requena L
Am J Dermatopathol; 2017 Jan; 39(1):e3-e7. PubMed ID: 28045754
[TBL] [Abstract][Full Text] [Related]
49. [Dermatomyositis as a paraneoplastic syndrome].
Wennekers MM; Appelman M; van der Weele WF
Ned Tijdschr Geneeskd; 2018; 161():D1916. PubMed ID: 29473536
[TBL] [Abstract][Full Text] [Related]
50. Two young-adult female cases of dermatomyositis with antibodies for transcriptional intermediary factor 1-γ.
Matsuura E; Ishiguro N; Katsumata Y; Urano W; Yamanaka H; Kondo M; Kuwana M; Kaji K; Hamaguchi Y; Fujimoto M; Kawashima M
Eur J Dermatol; 2012; 22(5):668-71. PubMed ID: 22992252
[TBL] [Abstract][Full Text] [Related]
51. Anti-Mi-2 and Anti-TIF1-γ Double-Positive Juvenile Dermatomyositis Treated under Diagnosis of Chronic Eczema: A Case Report.
Yoshida S; Matsumoto H; Fujita Y; Yokose K; Temmoku J; Matsuoka N; Yashiro-Furuya M; Asano T; Sato S; Suzuki E; Yago T; Yaguchi T; Aita T; Kusano M; Yamamoto T; Watanabe H; Migita K
Tohoku J Exp Med; 2022 Apr; 256(4):303-308. PubMed ID: 35296571
[TBL] [Abstract][Full Text] [Related]
52. Dermatomyositis associated with acute myelocytic leukemia.
Shrivastav A; Kumar V; Pal J
Rheumatol Int; 2010 Mar; 30(5):671-3. PubMed ID: 19471933
[TBL] [Abstract][Full Text] [Related]
53. Flare-up of dermatomyositis along with recurrence of breast cancer.
Osako T; Ito Y; Morimatsu A; Tada K; Sakurai N; Takahashi S; Akiyama F; Iwase T; Hatake K
Breast J; 2007; 13(2):200-2. PubMed ID: 17319865
[TBL] [Abstract][Full Text] [Related]
54. Identification of distinct cytokine/chemokine profiles in dermatomyositis with anti-transcriptional intermediary factor 1-γ antibody.
Zhao Q; Chen Y; Diao L; Zhang S; Wu D; Xue F; Xia Q; Li H; Zheng J; Cao H
Rheumatology (Oxford); 2022 May; 61(5):2176-2184. PubMed ID: 34508564
[TBL] [Abstract][Full Text] [Related]
55. Vesiculo-bullous dermatomyositis: report of three cases.
Nishigori K; Yamamoto T; Yokozeki H
Dermatol Online J; 2009 Apr; 15(4):6. PubMed ID: 19450399
[TBL] [Abstract][Full Text] [Related]
56. Pancreatic neuroendocrine tumor associated with humoral hypercalcemia of malignancy and carcinoid tumor: a case report and review of the literature.
Shah RH; Martinez D
Pancreas; 2013 Apr; 42(3):549-51. PubMed ID: 23211368
[No Abstract] [Full Text] [Related]
57. A Commercial Anti-TIF1γ ELISA Is Superior to Line and Dot Blot and Should Be Considered as Part of Routine Myositis-Specific Antibody Testing.
Mulhearn B; Li D; McMorrow F; Lu H; McHugh NJ; Tansley SL
Front Immunol; 2022; 13():804037. PubMed ID: 35154119
[TBL] [Abstract][Full Text] [Related]
58. SCLC, Paraneoplastic Dermatomyositis, Positive Transcription Intermediary Factor 1-γ, and Point Mutation in the Transcription Intermediary Factor 1-γ Coding Gene: A Case Report.
Arnon J; Elia A; Nevo Y; Lossos A; Nechushtan H
JTO Clin Res Rep; 2021 Sep; 2(9):100217. PubMed ID: 34590056
[TBL] [Abstract][Full Text] [Related]
59. Association of Anti-CCAR1 Autoantibodies With Decreased Cancer Risk Relative to the General Population in Patients With Anti-Transcriptional Intermediary Factor 1γ-Positive Dermatomyositis.
Fiorentino D; Mecoli CA; Igusa T; Albayda J; Paik JJ; Tiniakou E; Adler B; Mammen AL; Shah AA; Rosen A; Christopher-Stine L; Casciola-Rosen L
Arthritis Rheumatol; 2023 Jul; 75(7):1238-1245. PubMed ID: 36762496
[TBL] [Abstract][Full Text] [Related]
60. Anti-transcriptional intermediary factor 1 gamma antibodies in cancer-associated myositis: a longitudinal study.
Dani L; Holmqvist M; Martínez MA; Trallero-Araguas E; Dastmalchi M; Svensson J; Labrador-Horrillo M; Selva-O'Callaghan A; Lundberg IE
Clin Exp Rheumatol; 2020; 38(1):67-73. PubMed ID: 31365334
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
